A study testing whether a GLP-1 medicine from 4Moving Biotech, liraglutide, can ease joint pain.
What this means for you
- Who can join
- Adults 40 to 80, have knee osteoarthritis (joint pain), BMI 18.5+.
- What you take
- liraglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The study runs about 15 months.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Knee Osteoarthritis. Also studied in: Synovitis of Knee.
Full scientific study title: A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis.
Who can join
Adults 40 to 80, have knee osteoarthritis (joint pain), BMI 18.5+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Participants who have the capacity to give informed consent and who are willing to comply with all trial related procedures and assessments.
- Participants between 40 and 80 years of age.
- Female participant of childbearing potential (defined as any woman unless postmenopausal for at least one year or surgically sterile) must use highly effective methods of contraception as defined in the protocol. Highly effective contraceptive measures must be continued throughout the trial until the final visit.
- Bodyweight > 40 kg.
- Body mass index (BMI) >= 18.5 and <= 35.
Key exclusion criteria
- Pregnant or breastfeeding women.
- Significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the TK (varus > 10°, valgus > 10°) by radiography.
- Secondary OA such as joint dysplasia, aseptic osteonecrosis, joint infection, acromegaly, Paget disease, hemochromatosis, joint crystal disease or any inflammatory joint disease.
- Any known active infections including skin infections at the site injection or increased predisposition for the development of infections.
- Any partial knee replacement of the TK.
Where this study is enrolling
This trial has 3 sites across 3 states. Contact a site coordinator directly to start screening.
Arizona1 site
- Tucson Orthopaedic InstituteTucson, ArizonaNebojsa Skrepnik, MD
Illinois1 site
- Northwestern University Feinberg School of MedicineChicago, IllinoisThomas Schnitzer, MD
Massachusetts1 site
- Skylight Health Research BurlingtonBurlington, MassachusettsTimothy McAlindon, MD
Timeline
Started enrolling: 2025-06-17. Expected completion: 2026-09. Last updated on ClinicalTrials.gov: 2026-04-14.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
